TherapeuticsMD Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last twelve months. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TherapeuticsMD stock.
View analyst ratings for TherapeuticsMD or view top-rated stocks.

Wall Street analysts have given TherapeuticsMD a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but TherapeuticsMD wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

TherapeuticsMD is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for TherapeuticsMD.

TherapeuticsMD, Inc. (NASDAQ:TXMD) posted its quarterly earnings results on Thursday, May, 6th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by $0.01.
View TherapeuticsMD's earnings history.

TherapeuticsMD's stock was trading at $1.52 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TXMD shares have decreased by 21.1% and is now trading at $1.20.
View which stocks have been most impacted by COVID-19.

4 brokers have issued 12-month target prices for TherapeuticsMD's stock. Their forecasts range from $1.20 to $10.00. On average, they anticipate TherapeuticsMD's stock price to reach $5.07 in the next year. This suggests a possible upside of 322.2% from the stock's current price.
View analysts' price targets for TherapeuticsMD or view top-rated stocks among Wall Street analysts.

Some companies that are related to TherapeuticsMD include Protagonist Therapeutics (PTGX), Harmony Biosciences (HRMY), Cerevel Therapeutics (CERE), Madrigal Pharmaceuticals (MDGL), Supernus Pharmaceuticals (SUPN), Zymeworks (ZYME), Aurinia Pharmaceuticals (AUPH), Arcus Biosciences (RCUS), Applied Molecular Transport (AMTI), Constellation Pharmaceuticals (CNST), ADC Therapeutics (ADCT), Y-mAbs Therapeutics (YMAB), NGM Biopharmaceuticals (NGM), Amneal Pharmaceuticals (AMRX) and Indivior (INVVY).
View all of TXMD's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other TherapeuticsMD investors own include OPKO Health (OPK), Verastem (VSTM), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Cleveland-Cliffs (CLF), Novavax (NVAX) and Micron Technology (MU).

TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."

TherapeuticsMD's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.02%), Price T Rowe Associates Inc. MD (4.66%), Morgan Stanley (1.86%), Geode Capital Management LLC (1.41%), Ameriprise Financial Inc. (1.21%) and Northern Trust Corp (0.95%). Company insiders that own TherapeuticsMD stock include Angus C Russell, Brian Bernick, Edward Borkowski, Group L P Column, Jane F Barlow, John CK Iv Milligan, Marlan D Walker, Michael C Donegan, Robert G Finizio and Tommy G Thompson.
View institutional ownership trends for TherapeuticsMD.

TXMD stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Rubric Capital Management LP, Laurion Capital Management LP, Sanders Morris Harris LLC, Price T Rowe Associates Inc. MD, BNP Paribas Arbitrage SA, Virtu Financial LLC, and Credit Suisse AG. Company insiders that have sold TherapeuticsMD company stock in the last year include Edward Borkowski, Marlan D Walker, Michael C Donegan, and Robert G Finizio.
View insider buying and selling activity for TherapeuticsMD or view top insider-selling stocks.

TXMD stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Perceptive Advisors LLC, Perceptive Advisors LLC, Millennium Management LLC, Geode Capital Management LLC, Citigroup Inc., Northern Trust Corp, and Goldman Sachs Group Inc.. Company insiders that have bought TherapeuticsMD stock in the last two years include Angus C Russell, Brian Bernick, Group L P Column, Jane F Barlow, John CK Iv Milligan, Robert G Finizio, and Tommy G Thompson.
View insider buying and selling activity for TherapeuticsMD or or view top insider-buying stocks.

Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TXMD stock can currently be purchased for approximately $1.20.

TherapeuticsMD has a market capitalization of $471.83 million and generates $64.87 million in revenue each year. The company earns $-183,520,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis.

TherapeuticsMD employs 400 workers across the globe.

The official website for TherapeuticsMD is www.therapeuticsmd.com.

TherapeuticsMD is headquartered at 951 Yamato Road Suite 220, BOCA RATON FL, 33431.

TherapeuticsMD's mailing address is 951 Yamato Road Suite 220, BOCA RATON FL, 33431. The company can be reached via phone at 561-961-1900 or via email at [email protected]